menu
    • menu

    Company profile for Angiex

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Angiex is at the forefront of developing Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs), pioneering a first-in-class approach to tackle the fundamental drivers of cancer lethality. These innovative ND-ADCs from Angiex are designed to target a crucial intracellular transporter called TM4SF1. This transporter, abundantly present in the tumor microenvironment, facilitates the transport of proteins – including Angiex's ...
    Angiex is at the forefront of developing Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs), pioneering a first-in-class approach to tackle the fundamental drivers of cancer lethality. These innovative ND-ADCs from Angiex are designed to target a crucial intracellular transporter called TM4SF1. This transporter, abundantly present in the tumor microenvironment, facilitates the transport of proteins – including Angiex's antibodies – from the cell surface to the nucleus. This groundbreaking strategy holds promise for advancing cancer treatment by addressing key aspects of tumor biology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AngiexUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    150 CambridgePark Drive, 5th floor Cambridge, MA 02140
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://angiex.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/angiex-inc/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/angiexinc?lang=en-GB

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Angiex Secures $31M For Phase 1 Dose Escalation Of ADC AGX101
    Angiex Secures $31M For Phase 1 Dose Escalation Of ADC AGX101

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3189085/0/en/Angiex-Completes-Financings-Totaling-31-Million-to-Advance-Phase-1-Dose-Escalation-of-Nuclear-Delivered-ADC-AGX101-in-Patients-with-Advanced-Solid-Tumors.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    Abzena Supplies Clinical Trial Material For Angiex's AGX101 Study
    Abzena Supplies Clinical Trial Material For Angiex's AGX101 Study

    08 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/abzena-supplies-clinical-trial-material-for-angiexs-phase-i-study-of-agx101-a-first-in-class-tm4sf1-directed-adc-302218376.html

    PR NEWSWIRE
    08 Aug 2024
    Share Share
    Angiex Doses First Patient In Phase 1 Trial Of AGX101 For Solid Tumors
    Angiex Doses First Patient In Phase 1 Trial Of AGX101 For Solid Tumors

    07 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/07/2926298/0/en/Angiex-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-AGX101-a-novel-TM4SF1-Directed-Antibody-Drug-Conjugate-for-the-Treatment-of-Solid-Tumors.html

    GLOBENEWSWIRE
    07 Aug 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search